Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Return on Sales (2022 - 2025)

Historic Return on Sales for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to 187.4%.

  • BioXcel Therapeutics' Return on Sales fell 1011000.0% to 187.4% in Q3 2025 from the same period last year, while for Sep 2025 it was 88.0%, marking a year-over-year decrease of 493500.0%. This contributed to the annual value of 35.2% for FY2024, which is 948300.0% up from last year.
  • Per BioXcel Therapeutics' latest filing, its Return on Sales stood at 187.4% for Q3 2025, which was down 1011000.0% from 165.37% recorded in Q2 2025.
  • In the past 5 years, BioXcel Therapeutics' Return on Sales ranged from a high of 4496.0% in Q1 2022 and a low of 305.6% during Q3 2022
  • Its 4-year average for Return on Sales is 185.37%, with a median of 86.29% in 2024.
  • Its Return on Sales has fluctuated over the past 5 years, first tumbled by -47511000bps in 2023, then surged by 2090100bps in 2024.
  • Over the past 4 years, BioXcel Therapeutics' Return on Sales (Quarter) stood at 228.27% in 2022, then skyrocketed by 74bps to 59.48% in 2023, then soared by 35bps to 38.68% in 2024, then plummeted by -384bps to 187.4% in 2025.
  • Its Return on Sales was 187.4% in Q3 2025, compared to 165.37% in Q2 2025 and 82.22% in Q1 2025.